CA2516727C - Hypoxia inducible vegf plasmid for ischemic disease - Google Patents

Hypoxia inducible vegf plasmid for ischemic disease Download PDF

Info

Publication number
CA2516727C
CA2516727C CA2516727A CA2516727A CA2516727C CA 2516727 C CA2516727 C CA 2516727C CA 2516727 A CA2516727 A CA 2516727A CA 2516727 A CA2516727 A CA 2516727A CA 2516727 C CA2516727 C CA 2516727C
Authority
CA
Canada
Prior art keywords
prtp801
vegf
seq
plasmid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2516727A
Other languages
English (en)
French (fr)
Other versions
CA2516727A1 (en
Inventor
Minhyung Lee
Sung Wan Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of CA2516727A1 publication Critical patent/CA2516727A1/en
Application granted granted Critical
Publication of CA2516727C publication Critical patent/CA2516727C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA2516727A 2003-02-21 2004-02-23 Hypoxia inducible vegf plasmid for ischemic disease Expired - Fee Related CA2516727C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44896103P 2003-02-21 2003-02-21
US60/448,961 2003-02-21
PCT/US2004/005372 WO2004076633A2 (en) 2003-02-21 2004-02-23 Hypoxia inducible vegf plasmid for ischemic disease

Publications (2)

Publication Number Publication Date
CA2516727A1 CA2516727A1 (en) 2004-09-10
CA2516727C true CA2516727C (en) 2014-02-04

Family

ID=32927484

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2516727A Expired - Fee Related CA2516727C (en) 2003-02-21 2004-02-23 Hypoxia inducible vegf plasmid for ischemic disease

Country Status (9)

Country Link
US (2) US7638322B2 (cg-RX-API-DMAC7.html)
EP (1) EP1594549B1 (cg-RX-API-DMAC7.html)
JP (1) JP4652325B2 (cg-RX-API-DMAC7.html)
KR (1) KR101077689B1 (cg-RX-API-DMAC7.html)
AT (1) ATE456380T1 (cg-RX-API-DMAC7.html)
CA (1) CA2516727C (cg-RX-API-DMAC7.html)
DE (1) DE602004025328D1 (cg-RX-API-DMAC7.html)
ES (1) ES2339113T3 (cg-RX-API-DMAC7.html)
WO (1) WO2004076633A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ553162A (en) 2004-08-16 2010-03-26 Quark Biotech Inc Double stranded siRNA compounds that inhibit RRTP801
UY30097A1 (es) 2006-01-20 2007-08-31 Atugen Ag Usos terapeuticos de inhibidores de rtp801
WO2008054534A2 (en) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Screening systems utilizing rtp801
WO2007141796A2 (en) 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
WO2008106102A2 (en) 2007-02-26 2008-09-04 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104973A1 (en) * 1997-08-21 2003-06-05 Quark Biotech, Inc. Hypoxia-regulated genes
US6548633B1 (en) * 1998-12-22 2003-04-15 Genset, S.A. Complementary DNA's encoding proteins with signal peptides

Also Published As

Publication number Publication date
WO2004076633A3 (en) 2005-06-02
ATE456380T1 (de) 2010-02-15
US7638322B2 (en) 2009-12-29
US20110015257A1 (en) 2011-01-20
EP1594549B1 (en) 2010-01-27
JP2006518604A (ja) 2006-08-17
JP4652325B2 (ja) 2011-03-16
CA2516727A1 (en) 2004-09-10
DE602004025328D1 (de) 2010-03-18
EP1594549A4 (en) 2008-01-23
KR101077689B1 (ko) 2011-10-27
ES2339113T3 (es) 2010-05-17
WO2004076633A2 (en) 2004-09-10
US7998941B2 (en) 2011-08-16
EP1594549A2 (en) 2005-11-16
KR20050103302A (ko) 2005-10-28
US20070149467A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
RU2718248C2 (ru) Аденоассоциированные вирусные векторы для лечения лизосомных болезней накопления
JP2024041819A (ja) 合成dnaベクターおよびその使用
CN110835633B (zh) 利用优化的基因密码子扩展系统制备ptc稳定细胞系及应用
KR20210148227A (ko) 재조합 바이러스 벡터의 제조 방법
KR20220149588A (ko) 대사성 간 장애의 치료를 위한 조성물 및 방법
CN1997745A (zh) 癌症特异性启动子
KR101077689B1 (ko) 허혈성 질환용 저산소상태 유도성 혈관 내피 성장 인자플라스미드
KR20110126586A (ko) 단일 재조합 계 및 그의 사용 방법
CN107541526B (zh) 能敲低内源性ctla4表达的cik及制备方法与应用
CN112852860A (zh) 质粒载体及其在构建多拷贝表达系统中的应用
KR20210137427A (ko) Car t 세포 방법 및 작제물
CN107287239B (zh) 一种用于视网膜色素变性的基因治疗载体及药物
CN109055425B (zh) 一种带有黄色或红色荧光蛋白标签的非洲爪蟾卵母细胞表达载体及应用
CA2677475C (en) Expression of polypeptides from the nuclear genome of ostreococcus sp
KR102065917B1 (ko) Glb1 유전자를 발현하는 형질전환된 줄기세포 및 이를 포함하는 gm1 강글리오시드증 치료용 약학 조성물
CN109402155A (zh) 一种双控延迟裂解性质粒及其构建方法与应用
KR102283918B1 (ko) 인간인슐린유사성장인자 타입1 (hIGF1) 생산 발현용 벡터 및 상기 벡터로 형질전환된 미세조류
CN111471665B (zh) 一种dna环化分子及其用途
CN111909918B (zh) 一种内溶素突变体及其编码基因与应用
CN117597352A (zh) 基于微球菌素的羧酸化合物的制备方法和由此制备的基于微球菌素的羧酸化合物
CN116555318A (zh) 一种产反式橙花叔醇的解脂耶氏酵母基因工程菌及其构建方法和应用
WO2022251208A1 (en) Compositions and methods for improved treatment of x-linked myotubular myopathy
CN116554278A (zh) 变异型腺相关病毒及其在疾病治疗中的应用
KR102226252B1 (ko) 리소좀을 포함하는 미백용 조성물
KR102488647B1 (ko) 마크로코신 기반 카르복실산 화합물의 제조방법 및 이로부터 제조된 마크로코신 기반 카르복실산 화합물

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180223